Newsletter
Digital Health Insights
Expert analysis on longevity, GLP-1 therapies, synbiotics, digital health, and wellness innovation.
Latest issue 2026-10-22 · 6 pieces
Wellness innovation
Behaviour Change Beats One-Off Wellness Bookings
Wellness programmes that embed sustained daily habits outperform those focused solely on initial bookings and appointments.
2026-10-22 · Read the essay
- 02
GLP-1
GLP-1 Beyond Weight Loss: Access, Follow-Through, Gut Effects
GLP-1 therapies now require attention to access barriers, sustained patient follow-through, and gastrointestinal side effects that extend well past initial weight reduction goals.
- 03
Hospital AI
Hospital AI Links Imaging, Notes, and Command Oversight
Hospital AI now spans diagnostic imaging, automated documentation, real-time command centres, and formal governance structures that together reshape daily operations for clinicians and administrators.
- 04
Homecare
Nurse-Led Hospital-at-Home Models Reshape Acute Care Delivery
Hospital-at-home programs paired with nurse-managed remote monitoring let clinicians deliver hospital-level care inside patients' residences while maintaining safety and continuity.
- 05
Population health
Population Health Expansion in India and Peer Regions
Population health approaches are evolving across India, Southeast Asia, Africa, and the GCC to address chronic disease burdens and uneven service access through coordinated clinic and community efforts.
- 06
Digital Health
Shipping Integrated Digital Health: Records, Workflow, and Payment
Integrated digital platforms are embedding records management, daily clinic workflows, and payment processing into single operational systems that clinicians and operators can deploy without major disruption.
- 07
Digital Health
Clinic Systems That Handle Records, Workflow and Pay
Integrated digital tools are moving from pilots into daily clinic operations where records, scheduling and billing must align without extra staff effort.
- 08
GLP-1
GLP-1 Focus Shifts to Access, Follow-Through and Gut Effects
GLP-1 therapies now demand attention to real-world access barriers, sustained patient engagement, and gastrointestinal consequences that extend well past initial weight reduction.
